DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-822 N000

**NDA APPROVAL**

Boehringer Ingelheim Pharmaceuticals, Inc.
Attention: Mr. Charles Mazzarella
Associate Director, Drug Regulatory Affairs
900 Ridgebury Rd
P.O. Box 368
Ridgefield, CT 06877-0368

Dear Mr. Mazzarella:

Please refer to your supplemental new drug application dated December 20, 2007, received December 20, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Aptivus® (tipranavir) oral solution, 100mg/mL. Reference is also made to the Division's Approvable letter dated June 22, 2005.

We acknowledge receipt of your submissions dated:

| | | |
|---|---|---|
| May 10, 2005 | May 11, 2005 | May 13, 2005 |
| May 16, 2005 | June 3, 2005 | June 7, 2005 |
| March 5, 2008 | March 18, 2008 | April 7, 2008 |
| June 6, 2008 | | |

The December 20, 2007 submission constituted a complete response to our June 22, 2005 action letter for NDA 21-822.

This new drug application provides for the use of APTIVUS (Tipranavir oral solution), co-administered with ritonavir, for combination antiretroviral treatment of HIV-1 infected pediatric (age 2 to 18 years) patients who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

## CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at http://www.fda.gov/oc/datacouncil/spl.html that is identical to the enclosed labeling (text for the package insert, text for the patient package insert). Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "SPL for approved NDA 21-822."

## CARTON AND IMMEDIATE CONTAINER LABELS

We acknowledge your December 20, 2007 submission containing final printed carton and container labels.

## PEDIATRIC RESEARCH EQUITY ACT (PREA)

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We note that you have fulfilled the pediatric study requirement for this application.

## PROMOTIONAL MATERIALS

The Division of Drug Marketing, Advertising, and Communications (DDMAC) has reviewed the revised product labeling and has determined that it contains significant new risk information relating to your drug product. We are hereby requesting that all promotional materials for your drug product that include representations about the oral solution formulation of your drug product include the new risk information immediately.

These materials should include prominent disclosure of the important new information described in the WARNINGS and PRECAUTIONS section that appear in the revised package labeling. Please submit a written response to this request on or before June 30, 2008, stating whether you intend to comply with this request by facsimile at (301) 796-9878 or by mail to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see www.fda.gov/cder/ddmac.

## LETTERS TO HEALTH CARE PROFESSIONALS

If you issue a letter communicating important safety related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

All 15-day alert reports, periodic (including quarterly) adverse drug experience reports, field alerts, annual reports, supplements, and other submissions should be addressed to the original NDA 21-814 and NDA 22-292 for this drug product, not to this NDA. In the future, do not make submissions to this NDA except for the final printed labeling requested above.

If you have any questions, call Jaewon Hong, PharmD, Regulatory Project Manager, at (301) 796-2013.

Sincerely,

*{See appended electronic signature page}*

Debra Birnkrant, M.D.
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure

---

**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**

---

/s/
---
Jeffrey Murray
6/23/2008 04:58:31 PM